Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Adaptation of an L-proline adenylation domain to use 4-propyl-L-proline in the evolution of lincosamide biosynthesis

S. Kadlčík, T. Kučera, D. Chalupská, R. Gažák, M. Koběrská, D. Ulanová, J. Kopecký, E. Kutejová, L. Najmanová, J. Janata,

. 2013 ; 8 (12) : e84902.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Clinically used lincosamide antibiotic lincomycin incorporates in its structure 4-propyl-L-proline (PPL), an unusual amino acid, while celesticetin, a less efficient related compound, makes use of proteinogenic L-proline. Biochemical characterization, as well as phylogenetic analysis and homology modelling combined with the molecular dynamics simulation were employed for complex comparative analysis of the orthologous protein pair LmbC and CcbC from the biosynthesis of lincomycin and celesticetin, respectively. The analysis proved the compared proteins to be the stand-alone adenylation domains strictly preferring their own natural substrate, PPL or L-proline. The LmbC substrate binding pocket is adapted to accommodate a rare PPL precursor. When compared with L-proline specific ones, several large amino acid residues were replaced by smaller ones opening a channel which allowed the alkyl side chain of PPL to be accommodated. One of the most important differences, that of the residue corresponding to V306 in CcbC changing to G308 in LmbC, was investigated in vitro and in silico. Moreover, the substrate binding pocket rearrangement also allowed LmbC to effectively adenylate 4-butyl-L-proline and 4-pentyl-L-proline, substrates with even longer alkyl side chains, producing more potent lincosamides. A shift of LmbC substrate specificity appears to be an integral part of biosynthetic pathway adaptation to the PPL acquisition. A set of genes presumably coding for the PPL biosynthesis is present in the lincomycin--but not in the celesticetin cluster; their homologs are found in biosynthetic clusters of some pyrrolobenzodiazepines (PBD) and hormaomycin. Whereas in the PBD and hormaomycin pathways the arising precursors are condensed to another amino acid moiety, the LmbC protein is the first functionally proved part of a unique condensation enzyme connecting PPL to the specialized amino sugar building unit.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014552
003      
CZ-PrNML
005      
20201203122532.0
007      
ta
008      
150420s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0084902 $2 doi
035    __
$a (PubMed)24386435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kadlčík, Stanislav $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
245    10
$a Adaptation of an L-proline adenylation domain to use 4-propyl-L-proline in the evolution of lincosamide biosynthesis / $c S. Kadlčík, T. Kučera, D. Chalupská, R. Gažák, M. Koběrská, D. Ulanová, J. Kopecký, E. Kutejová, L. Najmanová, J. Janata,
520    9_
$a Clinically used lincosamide antibiotic lincomycin incorporates in its structure 4-propyl-L-proline (PPL), an unusual amino acid, while celesticetin, a less efficient related compound, makes use of proteinogenic L-proline. Biochemical characterization, as well as phylogenetic analysis and homology modelling combined with the molecular dynamics simulation were employed for complex comparative analysis of the orthologous protein pair LmbC and CcbC from the biosynthesis of lincomycin and celesticetin, respectively. The analysis proved the compared proteins to be the stand-alone adenylation domains strictly preferring their own natural substrate, PPL or L-proline. The LmbC substrate binding pocket is adapted to accommodate a rare PPL precursor. When compared with L-proline specific ones, several large amino acid residues were replaced by smaller ones opening a channel which allowed the alkyl side chain of PPL to be accommodated. One of the most important differences, that of the residue corresponding to V306 in CcbC changing to G308 in LmbC, was investigated in vitro and in silico. Moreover, the substrate binding pocket rearrangement also allowed LmbC to effectively adenylate 4-butyl-L-proline and 4-pentyl-L-proline, substrates with even longer alkyl side chains, producing more potent lincosamides. A shift of LmbC substrate specificity appears to be an integral part of biosynthetic pathway adaptation to the PPL acquisition. A set of genes presumably coding for the PPL biosynthesis is present in the lincomycin--but not in the celesticetin cluster; their homologs are found in biosynthetic clusters of some pyrrolobenzodiazepines (PBD) and hormaomycin. Whereas in the PBD and hormaomycin pathways the arising precursors are condensed to another amino acid moiety, the LmbC protein is the first functionally proved part of a unique condensation enzyme connecting PPL to the specialized amino sugar building unit.
650    _2
$a bakteriální proteiny $x chemie $7 D001426
650    _2
$a dipeptidy $x chemie $7 D004151
650    12
$a molekulární evoluce $7 D019143
650    _2
$a linkomycin $x biosyntéza $x chemie $7 D008034
650    _2
$a linkosamidy $x biosyntéza $x chemie $7 D055231
650    12
$a simulace molekulární dynamiky $7 D056004
650    _2
$a terciární struktura proteinů $7 D017434
650    _2
$a Streptomyces $x enzymologie $7 D013302
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kučera, Tomáš, $d 1984- $7 uk2015876426 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Chalupská, Dominika $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Gažák, Radek $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Koběrská, Markéta $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Ulanová, Dana $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Kopecký, Jan, $d 1966- $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. $7 xx0108100
700    1_
$a Kutejová, Eva $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic ; Department of Biochemistry and Structural Biology, Institute of Molecular Biology, Slovac Academy of Sciences, Bratislava, Slovakia.
700    1_
$a Najmanová, Lucie $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Janata, Jiří $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 12 (2013), s. e84902
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24386435 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20201203122529 $b ABA008
999    __
$a ok $b bmc $g 1072133 $s 897430
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 8 $c 12 $d e84902 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20150420

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...